Immunotherapy for Urothelial Carcinoma: Current Status and Perspectives
Intravesical instillation of bacillus Calmette Guérin (BCG) for the treatment of urothelial carcinoma (UC) of the bladder is based on the BCG-induced immune response, which eradicates and prevents bladder cancer. The results of recent studies have suggested that not only major histocompatibility com...
Main Authors: | Taiji Tsukamoto, Hiroshi Kitamura |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2011-07-01
|
Series: | Cancers |
Subjects: | |
Online Access: | http://www.mdpi.com/2072-6694/3/3/3055/ |
Similar Items
-
Urothelial carcinoma: the evolving landscape of immunotherapy for patients with advanced disease
by: Dietrich B, et al.
Published: (2018-01-01) -
Do Cancer Genetics Impact Treatment Decision Making? Immunotherapy and Beyond in the Management of Advanced and Metastatic Urothelial Carcinoma
by: Gavin Hui, et al.
Published: (2023-08-01) -
Immunotherapy for Urothelial Carcinoma: Focus on Clinical Utility of Nivolumab
by: Chiang RS, et al.
Published: (2022-10-01) -
Current Status and Future Perspectives of Immunotherapy for Locally Advanced or Metastatic Urothelial Carcinoma: A Comprehensive Review
by: Tae Jin Kim, et al.
Published: (2020-01-01) -
Novel immunotherapy in the management of advanced urothelial cancer - review of the literature
by: Paulina Chmiel, et al.
Published: (2022-08-01)